SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NGL Fine-Chem - Quaterly Results

10 Nov 2021 Evaluate
The company witnessed a 15.09% growth in the revenue at Rs. 784.97 millions for the quarter ended September 2021 as compared to Rs. 682.07 millions during the year-ago period.The Net Profit of the company registered a slight decline of -4.10% to Rs. 141.89  millions from Rs. 147.96 millions.Operating Profit reported a sharp decline to 214.34 millions from 215.73 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 784.97 682.07 15.09 1544.06 1106.31 39.57 2552.08 1521.81 67.70
Other Income 48.87 28.54 71.23 98.09 51.08 92.03 115.21 33.35 245.46
PBIDT 214.34 215.73 -0.64 494.83 364.39 35.80 852.31 238.71 257.05
Interest 4.02 5.44 -26.10 7.72 11.46 -32.64 18.40 22.53 -18.33
PBDT 210.32 210.29 0.01 487.11 352.93 38.02 833.91 216.18 285.75
Depreciation 19.56 18.14 7.83 38.89 36.81 5.65 73.94 72.65 1.78
PBT 190.76 192.15 -0.72 448.22 316.12 41.79 759.97 143.53 429.49
TAX 48.87 44.19 10.59 112.84 79.43 42.06 205.28 37.49 447.56
Deferred Tax 4.87 0.39 1148.72 8.84 7.13 23.98 14.58 -11.95 -222.01
PAT 141.89 147.96 -4.10 335.38 236.69 41.70 554.69 106.04 423.10
Equity 30.89 30.89 0.00 30.89 30.89 0.00 30.89 30.89 0.00
PBIDTM(%) 27.31 31.63 -13.67 32.05 32.94 -2.70 33.40 15.69 112.91

NGL Fine-Chem Share Price

2229.75 -25.30 (-1.12%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×